Efficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized by Candida Species and Previous Genital Tract Infection: A Post Hoc Analysis of a Phase 3 Trial
Xiaoqian Wang, Fengxia Xue, Chunlian Zhang, Ruifang An, Hongjie Ruan, Liancheng Zhu, Liping Zhang, Qinping Liao · 2026
Read Efficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized by Candida Species and Previous Genital Tract Infection: A Post Hoc Analysis of a Phase 3 Trial by Xiaoqian Wang, Fengxia Xue, Chunlian Zhang, Ruifang An, Hongjie Ruan, Liancheng Zhu, Liping Zhang, Qinping Liao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13245468.txt.
Description
Xiaoqian Wang and colleagues recheck a new yeast infection drug by patient subgroups in a 2026 trial analysis. Oteseconazole had beaten the standard drug fluconazole for severe vaginal yeast infection in a phase 3 trial. Whether the edge held across yeast species and patient histories was untested.
The analysis covers 319 trial patients split by yeast type and by past genital infection. Cure rates at four weeks favored the new drug in every subgroup. The edge held for the common yeast and for rarer types alike. Side effect rates stayed close between the two drugs throughout. The results widen confidence in the new drug for tough cases.
Catalog record
| CREATOR | Xiaoqian Wang, Fengxia Xue, Chunlian Zhang, Ruifang An, Hongjie Ruan, Liancheng Zhu, Liping Zhang, Qinping Liao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |